Switch theme
Sign up to access all valuation multiples
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
2010
353
LTM Revenue $57.9M
LTM EBITDA -$333M
-$8.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sage Therapeutics has a last 12-month revenue (LTM) of $57.9M and a last 12-month EBITDA of -$333M.
In the most recent fiscal year, Sage Therapeutics achieved revenue of $41.2M and an EBITDA of -$409M.
Sage Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sage Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $57.9M | XXX | $41.2M | XXX | XXX | XXX |
| Gross Profit | $50.5M | XXX | $31.8M | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 77% | XXX | XXX | XXX |
| EBITDA | -$333M | XXX | -$409M | XXX | XXX | XXX |
| EBITDA Margin | -575% | XXX | -993% | XXX | XXX | XXX |
| EBIT | -$353M | XXX | -$411M | XXX | XXX | XXX |
| EBIT Margin | -609% | XXX | -995% | XXX | XXX | XXX |
| Net Profit | -$325M | XXX | -$401M | XXX | XXX | XXX |
| Net Margin | -561% | XXX | -971% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sage Therapeutics's stock price is $6.
Sage Therapeutics has current market cap of $404M, and EV of -$8.1M.
See Sage Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$8.1M | $404M | XXX | XXX | XXX | XXX | $-5.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sage Therapeutics has market cap of $404M and EV of -$8.1M.
Sage Therapeutics's trades at -0.2x EV/Revenue multiple, and 0.0x EV/EBITDA.
Equity research analysts estimate Sage Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sage Therapeutics has a P/E ratio of -1.2x.
See valuation multiples for Sage Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $404M | XXX | $404M | XXX | XXX | XXX |
| EV (current) | -$8.1M | XXX | -$8.1M | XXX | XXX | XXX |
| EV/Revenue | -0.1x | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBITDA | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBIT | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/Gross Profit | -0.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.2x | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSage Therapeutics's last 12 month revenue growth is 65%
Sage Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.3M for the same period.
Sage Therapeutics's rule of 40 is -566% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sage Therapeutics's rule of X is -413% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sage Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 65% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -575% | XXX | -993% | XXX | XXX | XXX |
| EBITDA Growth | -37% | XXX | -35% | XXX | XXX | XXX |
| Rule of 40 | -566% | XXX | -928% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -413% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 548% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1072% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sage Therapeutics acquired XXX companies to date.
Last acquisition by Sage Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Sage Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sage Therapeutics founded? | Sage Therapeutics was founded in 2010. |
| Where is Sage Therapeutics headquartered? | Sage Therapeutics is headquartered in United States of America. |
| How many employees does Sage Therapeutics have? | As of today, Sage Therapeutics has 353 employees. |
| Who is the CEO of Sage Therapeutics? | Sage Therapeutics's CEO is Mr. Barry E. Greene. |
| Is Sage Therapeutics publicy listed? | Yes, Sage Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Sage Therapeutics? | Sage Therapeutics trades under SAGE ticker. |
| When did Sage Therapeutics go public? | Sage Therapeutics went public in 2014. |
| Who are competitors of Sage Therapeutics? | Similar companies to Sage Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sage Therapeutics? | Sage Therapeutics's current market cap is $404M |
| What is the current revenue of Sage Therapeutics? | Sage Therapeutics's last 12 months revenue is $57.9M. |
| What is the current revenue growth of Sage Therapeutics? | Sage Therapeutics revenue growth (NTM/LTM) is 65%. |
| What is the current EV/Revenue multiple of Sage Therapeutics? | Current revenue multiple of Sage Therapeutics is -0.1x. |
| Is Sage Therapeutics profitable? | Yes, Sage Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sage Therapeutics? | Sage Therapeutics's last 12 months EBITDA is -$333M. |
| What is Sage Therapeutics's EBITDA margin? | Sage Therapeutics's last 12 months EBITDA margin is -575%. |
| What is the current EV/EBITDA multiple of Sage Therapeutics? | Current EBITDA multiple of Sage Therapeutics is 0.0x. |
| What is the current FCF of Sage Therapeutics? | Sage Therapeutics's last 12 months FCF is -$287M. |
| What is Sage Therapeutics's FCF margin? | Sage Therapeutics's last 12 months FCF margin is -495%. |
| What is the current EV/FCF multiple of Sage Therapeutics? | Current FCF multiple of Sage Therapeutics is 0.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
